These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26590027)

  • 1. Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists.
    Jaeger M; Ghisleni EC; Fratini L; Brunetto AL; Gregianin LJ; Brunetto AT; Schwartsmann G; de Farias CB; Roesler R
    Childs Nerv Syst; 2016 Jan; 32(1):61-4. PubMed ID: 26590027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gastrin-releasing peptide receptor antagonist stimulates Neuro2a neuroblastoma cell growth: prevention by a histone deacetylase inhibitor.
    Abujamra AL; Almeida VR; Brunetto AL; Schwartsmann G; Roesler R
    Cell Biol Int; 2009 Aug; 33(8):899-903. PubMed ID: 19426821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.
    Jaeger M; Nör C; de Farias CB; Abujamra AL; Schwartsmann G; Brunetto AL; Roesler R
    Childs Nerv Syst; 2013 Dec; 29(12):2145-50. PubMed ID: 24092425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
    Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells.
    Schmidt AL; de Farias CB; Abujamra AL; Kapczinski F; Schwartsmann G; Brunetto AL; Roesler R
    J Mol Neurosci; 2010 Mar; 40(3):303-10. PubMed ID: 19642024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibition prevents the impairing effects of hippocampal gastrin-releasing peptide receptor antagonism on memory consolidation and extinction.
    Petry FS; Dornelles AS; Lichtenfels M; Valiati FE; de Farias CB; Schwartsmann G; Parent MB; Roesler R
    Behav Brain Res; 2016 Jul; 307():46-53. PubMed ID: 27025446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced NGF secretion by HT-29 human colon cancer cells treated with a GRPR antagonist.
    de Farias CB; Stertz L; Lima RC; Kapczinski F; Schwartsmann G; Roesler R
    Protein Pept Lett; 2009; 16(6):650-2. PubMed ID: 19519524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.
    Nör C; Sassi FA; de Farias CB; Schwartsmann G; Abujamra AL; Lenz G; Brunetto AL; Roesler R
    Mol Neurobiol; 2013 Dec; 48(3):533-43. PubMed ID: 23516101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
    Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
    Nör C; de Farias CB; Abujamra AL; Schwartsmann G; Brunetto AL; Roesler R
    Childs Nerv Syst; 2011 Jun; 27(6):897-901. PubMed ID: 21560052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
    J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
    Yuan J; Llamas Luceño N; Sander B; Golas MM
    Cell Oncol (Dordr); 2017 Jun; 40(3):263-279. PubMed ID: 28429280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells.
    Shin JA; Han G; Kim HJ; Kim HM; Cho SD
    Eur J Cancer Prev; 2014 Jul; 23(4):277-85. PubMed ID: 24871559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
    Ecker J; Oehme I; Mazitschek R; Korshunov A; Kool M; Hielscher T; Kiss J; Selt F; Konrad C; Lodrini M; Deubzer HE; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
    Acta Neuropathol Commun; 2015 Apr; 3():22. PubMed ID: 25853389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
    Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma.
    da Cunha Jaeger M; Ghisleni EC; Cardoso PS; Siniglaglia M; Falcon T; Brunetto AT; Brunetto AL; de Farias CB; Taylor MD; Nör C; Ramaswamy V; Roesler R
    J Mol Neurosci; 2020 Jun; 70(6):981-992. PubMed ID: 32056089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats.
    Roesler R; Kopschina MI; Rosa RM; Henriques JA; Souza DO; Schwartsmann G
    Eur J Pharmacol; 2004 Feb; 486(1):35-41. PubMed ID: 14751406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma.
    Damgé C; Hajri A
    Eur J Pharmacol; 1998 Apr; 347(1):77-86. PubMed ID: 9650851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma.
    Kanashiro CA; Schally AV; Cai RZ; Halmos G
    Anticancer Drugs; 2005 Feb; 16(2):159-65. PubMed ID: 15655413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.